Talicia Holdings Patent-Cliff Exposure & CMS Drug Spending Portfolio

Talicia Holdings (US): 1 reconciled FDA prescription therapies, $7.2M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2042-01-01
2024 CMS Total Public Spend$7.2M
2024 Medicare Part D Spend$2.6M
2024 Medicaid Spend$4.6M
California HCAI SB 17 Filings6 WAC filings (max 21.4% 2-yr change)